Loading
Latest filing published 29 Jul 2026 for Scribe Therapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
All filings by AH Bio Fund II, L.P. on record concern Scribe Therapeutics, Inc. Altogether 3 filings, all relating to 27 July 2026.
Purchases make up the whole of the open-market record (1 purchase, €4.4M). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
On 29 July 2026 came the latest disclosure, a transaction in Scribe Therapeutics, Inc. The latest purchase dates back some time: it was published 87 days ago, on 29 July 2026. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations